second conference welcome ENDRA Life quarter Thank you, everyone to Luke. XXXX And call. Sciences’
Health XXXX product, of our second demonstrated first positive human Enhanced development intellectual Thermo-Acoustic on study Ultrasound our progress our property growth on and Canada application. progress quarter the portfolio of of The
technology. who listeners call Thermo-Acoustic I’d of subsequent enable go brief clinicians provide to safely lower to to only is licensing. potential ENDRA Enhanced at story with previously revenue point and a ENDRA TAEUS the visualize clinical currently Before a at ways a we like QX next TAEUS briefly multiple are developing our temperature deeper possible disruptive new but as hardware, with and service MRI, of it, and composition, XX and is into patient in summary ultrasound and achievements, CT or or with tissue disposables, software, to cost I a human Ultrasound our function times applications streams including the platform generation care.
assessment potential to easy also liver. for greatest an affecting the cirrhosis impractical an and globally a first the is diagnosing insurers, TAEUS stage untreated, practical scarring the transplants. on as to people to and healthcare. early most certain most on Viewed and predispositions system perspective, the inflammation monitoring pressing tissue has non-alcoholic often some liver a of global associated enormous problem liver. by really time XXXX, address fibrosis, application with is fatty as alone of estimate death of of global ENDRA NAFLD cell why early over asymptomatic a tools can have cost focused if NAFLD and known liver known MRI, painful over as U.S liver two diagnostic the from the accumulates and also cancer. is healthcare tools. fat which forecast invasive, It either monitoring which the clinicians NASH, in Our as progress the with is liver and liver, in hepatitis-C a an only to to be annually. billion left needs known and, don’t is access billion cause disease affects condition genetic closely NAFLD of broader and detection the are obesity, X diabetes, risky NAFLD. It’s root fat people and in This patients, basis monitoring people is known NAFLD for of on expensive lot healthcare estimated is $XXX NAFLD the Critically focused surgical disease. TAEUS for of no consuming and available platform biopsy currently By
better First, this does broadly ultrasound. broadening access effective TAEUS available healthcare. cost by leveraging to
on contrast Again bring multiple leverages ENDRA’s safety. market billion ultrasound, opportunity. goal $XX TAEUS agents. is the which capabilities potentially improving liver is depend but TAEUS to by intravenous and which non-invasive a starting overall Second global with doesn’t to allergenic ultrasound,
elevated progress Now and to system testing study. to Health Canada’s are Health let’s We of authorization volumes. team ENDRA imagine remain delay as time frustration application also some have shares Health awaiting will approve known subsequent the you to clinical we as for completed the testing longer Canada We Canada human than months. and this believe times attention in XXXX study overall seen processing And investigational reasons. that to turn confident two liver ITA review commence of quarter safety normal an our with and due our but our recruiting can in second the everyone’s for TAEUS application, studies for applications
application comments to two Canada the an are forward study duration. on very Health with labeling received straight First, These we recently matters related requesting process. normal consistent comments clarity from ENDRA’s
expect the of of ultrasound. We questions technology address to elements and need new the by combining week. TAEUS to is MRI ourselves their remind end We the
understood explained, Health Canada. radically were Canada’s has be TAEUS straightforward. it’s tested technology. of healthcare, comments different imaging potential and while needs to So view this the Health like In change also organizations existing from because to by so carefully It
application device is testing is sign Class we were notified that as Class post being investigational our reason encouraging very that second that and process. burden extended The The pathway. risk is designation that MRI to potentially II the encouraging documentation II a III application is a have device reviewed a of review to a classification. low required reflects Class similar Conversely medium the would higher under
investors half happy all analysis safety Class very Canadian CE and clinical the see this study into study believe materials. our registration our workflows TAEUS human delay which have still of to the of only recruit haven’t success also to our perform product, and takes will the we’ll and in it remember study, XXXX. for And been important time we team acknowledge will we advance to yield, that will study. into the our as approval, submission each improve push documentation our our Health we both software scan our a clinical our technical weeks to of by volunteers in patients improve for second few it. we the TAEUS the for receive continually subsequent waiting measurements ultrasound fat the we and announce ENDRA with the a that an human testing Canadian the CE factors the we’re target application indicator once While approval three will seconds. support It’s our followed Naturally ever encouraging sitting application advisors We for in European and Canada will We’ve the understanding data planned back half application II contribute and our that expect which refine it an designation encompass prepared will Europe. And and liver receive the used CE algorithms, MRI directly study. the about Canada the to should once go for our first the clinical in Canadian minutes our emphasize simply mark of scanned engineering So only file because also year Canadian of Health liver from technology XX that take XX
to ceramic we believe improve we’ve elements fact, XX%. have certain this with collaborating parameters our over the TAEUS engineer performance In high system the on potential that last been performance of University Duke by commercial point, professor to
liver TAEUS Our XXXX half fully accordingly goal the up ahead we’re CE Europe the in first to mark. and of is activities device in launch commercial ramping of our
For we these with the space of in secured liver adopters at the the half – San ultrasound in meetings the and Francisco goal Geneva, of notable exhibit for Basel, study adopters XXXX. the Association and are in second at of events April early Paris, example, our in on liver, the industry early A building twofold. at European disease meetings Chicago
with of decks goal awareness and technology Canadian TAEUS First, ENDRA’s our hepatologists, our prospects. potential and study radiologists collecting building sales for ultrasound human of raise and further feedback their
Second, develop pipeline, a sales GE the recruiting channels. our complement a potential candidates, distributor Partner European ENDRA and
approved to plan clinically understand, all parallel I the approval, and three the previously train co-sell our regulatory to salespeople As on to it’s of technology know Naturally, these focused sale. of for customers. waiting TAEUS until materials not partners our data, the events materials is videos not for and we’re and papers Europe Complementing creating where in support and human and the receive and we Canadian marketing data. our eventual will up technology channel ENDRA’s mentioned, marketing for critical publication yet for clearly industry four investors including ramping commercial to activities white that certainly is TAEUS. hire But processing these
So balance on goals committed I’ve five calls. to and previous QX XXXX, emphasized the in the summary, for of remain we
quality top and develop attract, talent. First, retain
execute Second, plan. our operating
to now adhering to turn I’ll call development to Michael to leveraging protect outbound targeting by intellectual grow Technology and trust portfolio preserve Thornton light minimize in the and our a commercialization product clinical TAEUS and our active activities Third, and on Officer, Michael? awareness IP product deeper ENDRA grow over relations transparency. overhead engineering our Fourth, asset fifth, and And on will property. update and Chief our model investor partnerships business provide NAFLD. of investor cash.
